BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Progenitor Labs of Plasticell Named Best Emerging Biotech


10/12/2011 7:47:55 AM

London 12 Oct 2011 - Progenitor Labs, the biotechnology company spun out of Plasticell in 2011, is pleased to announce it has been voted Best Emerging Biotech at the Oxford Biotechnology Network’s Annual Awards Dinner held at Pembroke College, Oxford on 13th Sep, 2011. Progenitor was selected from the biotechnology companies clustered within the “Golden Triangle” comprising London, Oxford and Cambridge.

Progenitor is focused on discovery of natural and synthetic molecules that regenerate tissues of the human body. The new venture brings together proven high throughput technologies with a deep understanding of stem cell biology. The key proprietary technology, ProScreen™, is a drug screen for molecules that can regenerate cells by acting on adult stem cells resident in the body. In addition the Company has obtained an exclusive license to CombiCult™, Plasticell’s award-winning combinatorial technology, for use in regenerative drug discovery.

Progenitor’s focus on drug development distinguishes the Company from other regenerative medicine companies that are focused on cell therapies. Development of regenerative drugs circumvents the ethical debate to which conventional stem cell therapies are still subject. Moreover, drugs have substantial advantages over cell therapies: they are easier to develop, manufacture, distribute, store, administer and market.

Accepting the award on behalf of Progenitor, Mr. Dennis Saw, CFO, remarked: “From its inception, Progenitor has been extremely well received by one and all in the biotechnology community. I am delighted our exciting business model and technologies have been formally recognized at this prestigious OBN event.”

For more information on Progenitor Labs, please contact Yen Choo, CEO, at yen@progenitorlabs.com, or visit www.progenitorlabs.com

For more information about Plasticell Limited please go to: www.plasticell.co.uk



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES